Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
Date: 09 August 2025
To
The Secretary BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001 Scrip Code: 544293
Dear Sir / Ma’am,
The Secretary The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051 Scrip Symbol : SURAKSHA
Reg: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
Sub: Presentation to be made at the Analyst(s) / Investor(s) Meet/ Conference- Earnings Call
Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 31 July 2025 regarding schedule of Analyst(s)/ Investor(s) Meet /Conference i.e Earnings Call on Monday, 11 August 2025 at 11:00 am (IST), we are hereby enclosing a copy of Investor Presentation on the unaudited (standalone and consolidated) financial results of the Company for quarter and three months ended 30 June 2025.
The Investor Presentation will be exhibited at the aforesaid Earnings Call and the same will be made available at https://www.surakshanet.com/pdf/investor/Suraksha%20Investor%20Presentation%20Q1%20FY% 202025-26.pdf
Company
website
the
the
on
of
Please note that the schedule of the aforesaid Earnings Call is subject to change. The changes might happen due to exigencies on the part of the Company/ Analyst(s)/ Investor(s).
This may please be informed to all the concerned.
For Suraksha Diagnostic Limited
_________________ Mamta Jain Company Secretary & Compliance Officer
Encl: As above
Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New
Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750
SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q1 FY26
Safe Harbor Statement
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
Suraksha Diagnostic Limited| Investor Presentation
2
Q1 FY26 Highlights
Q1 FY26 At A Glance
as of 30 June 2025
9
Labs
58
Diagnostic Centres
170
Collection Centres
0.34 million
1.92 million
₹ 2,101
Patients Served (Q1 FY26)
Tests Performed (Q1 FY26)
Revenue per patient (Q1 FY26)
314
Doctors
7
26
CT Machines
₹ 707
EBITDA per patient (Q1 FY26)
15
₹ 38 million
NABL accredited labs
MRI Machines
Revenue per lab (Q1 FY26)
Note: National Accreditation Board for Testing and Calibration Laboratories (NABL) Suraksha Diagnostic Limited| Investor Presentation
4 4
Consolidated Financial Performance – Q1 FY26
Total Income (₹ million)
EBITDA (₹ million)
PAT (₹ million)
35.8%
30.7%
34.0%
12.6%
11.0%
12.6%
+19%
659
735
618
+14%
200
217
247
+20%
72
77
92
Q1 FY25
Q4 FY25
Q1 FY26
Q1 FY25
Q4 FY25
Q1 FY26
Q1 FY25
Q4 FY25
Q1 FY26
Suraksha Diagnostic Limited| Investor Presentation
5
Key Performance Metrics For Q1 FY26
Number of Centres
58
47
Q1 FY25
Q1 FY26
Revenue / Patient (₹)
2121
2101
Number of Tests (million)
1.92
1.52
Q1 FY25
Q1 FY26
EBITDA / Patient(₹)
752
707
Suraksha Diagnostic Limited| Investor Presentation
Q1 FY25
Q1 FY26
Q1 FY25
Q1 FY26
6 6
Profit & Loss Statement (Consolidated)
Particulars (₹ million)
Revenue from Operations
Other Income
Total Revenue
Cost of Material Consumed
Employee Benefit Expenses
Other Expenses
Impairment Loss
EBITDA
EBITDA Margin (%)
Depreciation
Finance Cost
Profit before Tax & Exceptional Item
Exceptional Item
Profit before Tax
Profit before Tax (%)
Tax
Profit After Tax PAT Margin (%) EPS
Q1 FY26 725.86
Q1 FY25 607.32
9.06
734.92
87.51
127.75
282.01
-8.90
246.56
34.0%
94.82
27.05
124.69
0.00
124.69
17.2%
32.94
91.75 12.6% 1.80
11.17
618.48
66.37
103.79
229.53
1.58
217.21
35.8%
89.93
22.15
105.13
0.00
105.13
17.3%
28.46
76.67 12.6% 1.49
Y-o-Y
18.83%
13.51%
18.60%
18.60%
19.67%
Q4 FY25 650.95
8.17
659.12
88.48
102.03
260.53
8.02
200.05
30.7%
87.29
20.63
92.13
0.00
92.13
14.2%
20.42
71.71 11.0% 1.42
Q-o-Q
11.50%
23.25%
35.35%
35.35%
27.95%
Suraksha Diagnostic Limited| Investor Presentation
7
Expanding Offerings Through Strategic Acquisition
ABOUT FETOMAT
•
•
•
•
Incorporated in May 2021, Fetomat Wellness Private Limited (“Fetomat”) is a network of fertility and pregnancy care clinics
Fetomat focuses on pregnancy care, women’s ultrasound scans, prenatal diagnostics, genetic counselling and medical training for doctors
Fetomat is one of Eastern India’s leading centers for fetal and maternal medicine and operated 2 centers as of 31 March 2024
For FY24, Fetomat’s turnover was ₹ 4.11 crore with an EBITDA of ₹ 0.56 crore
Key Highlights of Strategic Investment
In March 2025, the Board approved a proposal for a strategic investment in Fetomat
Upon deal completion on 09 April 2025, we held 63% stake in Fetomat
This strategic acquisition will help integrate fetal medicine expertise into our existing healthcare framework
Suraksha Diagnostic Limited| Investor Presentation
The synergies with Fetomat will enhance innovation in fetal medical diagnostics, strengthening our industry position
8
Genomics Could Be The Next Growth Lever
ABOUT GENOMICS VERTICAL
Global Genetic Testing Market Size ($ Bn)
•
•
•
•
•
In July 2025, we announced the launch of Suraksha Genomics, a new vertical for advanced genetic and molecular testing services
Suraksha Genomics offers robust infrastructure and critical capabilities across prenatal diagnostics (QF-PCR, Karyotyping, FISH, Microarray, NIPT), inherited disease analysis (including single-gene mutation detection and whole exome sequencing), pharmacogenomics, and oncology-focused molecular panels
Focused on scaling into high-impact domains such as whole genome and metagenomic testing, AI integration and laying the groundwork for population-scale genomic screening initiatives
Aim to contribute to national priorities such as rare disease diagnosis, newborn screening, and preventive genomics, while also expanding research and public health initiatives
Total investments: ₹ 220 million; Incremental investment over the next 24 months: ₹ 460 million
38.77
186.64
Suraksha Diagnostic Limited| Investor Presentation
2024
2035E
9
Company Overview
Evolution To The Largest Integrated Diagnostic Chain In East India
Built fully comprehensive diagnostic centre, under brand ‘Suraksha’
5 centres
Received second round of funding from OrbiMed
Exit of Lighthouse Funds
25 centres
4 Labs
53 centres
9 Labs
IPO and listing on BSE and NSE
1992
2007
2010
2013
2016
2020
2024
2025
Launched the first centre of the Company
1 centre
Received first round of funding from PE investor Lighthouse Funds
Acquisition of 2 pre- existing diagnostic centres in Kolkata from Future Medical & Research Trust
Suraksha Diagnostic Limited| Investor Presentation
Acquisition of Fetomat Wellness Private Limited (63% stake)
Launch of Suraksha Genomics
58 centres
11
Deeply Entrenched In The Vital Geography Of West Bengal
2
2
55 Centers in West Bengal
•
•
•
4th most populous state in India Fragmented market with low penetration of chained diagnostic centers Accounted for 95.5% of FY24 Revenue from operations
Bihar
Assam
West Bengal
Meghalaya
1
No. of centres
>10 centres
3 centres
2 centres
1 centres
Population Legend
No. of people >8.5 mn
6.0 – 8.5 mn
4.0 – 6.0 mn
2.0 – 4.0 mn
<2.0 mn
1
1
2
1
Helabattala
3
Bardhaman
21
SRPL-Garden Reach
2
Shyamnagar
1
2
11
2
3
Suraksha Diagnostic Limited| Investor Presentation
12
Hub & Spoke Operating Model
Modalities Offered
Key Stats
s e r t n e C b u H
s e r t n e C e k o p S
Large
Centres
Medium Centres
Small Centres
MRI
CT Scan
USG
Gastroenterology Neurology
Pathology
X-Ray
Cardiology
Mammo
OPG
Dexa
CT-Scan
USG
X-Ray
Neurology
Cardiology
Pathology
# of doctors & employees / centre
Area
30-40
5,000 – 8,000 sq. ft
20-25
2,500 – 5,000 sq. ft
12-15
1,500 – 3,500 sq. ft
USG
X-Ray
Cardiology
Pathology
Note: 1) as of 30 June 2025
Suraksha Diagnostic Limited| Investor Presentation
13
Demonstrated success in Kolkata region with significant potential for future growth2
…..With Demonstrated Success
Operational Network(1)
1 Central Lab
8 Satellite Labs
18 Hub Centres
(co-located with hub centres)
(equipped to conduct all pathology sample collection, basic and advanced radiology tests)
13 Medium Centres
25 Small Centres
4 PPP
170 Sample Collection Centres
Spoke Centres
(equipped to conduct all pathology sample collection and certain basic & intermediate radiology tests)
Enhanced brand penetration through ability to serve more customers
Unlocks economies of scale
Hub centres Offers pathology tests, basic & advanced radiology tests
Spoke centres Offers pathology tests, basic and intermediate radiology tests
Note: 1) as of 30 June 2025; 2) Map illustrating the ‘hub and spoke’ model in the diagnostic centre network in Greater Kolkata, representing clusters formed by combining the hub centres and spoke centres
Suraksha Diagnostic Limited| Investor Presentation
14
Well-established Operational Network - Greater Economies Of Scale
Report Flow
Patient
Image/Report Flow
Image Flow
Patients Flow
Doctor
Polyclinic Doctor
Hospital
Customers
Samples
Sample Flow
Patient Flow
Suraksha Diagnostic Limited| Investor Presentation
P.A.C.S (Software)
RAD (Scrutiny)
IMAGE (Report)
#18
Hub Centre
#42
Spoke Centre
Collection Centre #170
Home Collection
#1 Flagship Reference Lab
#8
SATELLITE LAB
15
Well Equipped Clinical Infrastructure
Suraksha Diagnostic Limited| Investor Presentation
16
Customer Convenience Through Value Added Services
Value Added Services enhancing customer experience and convenience
Home Collection
Allows samples to be collected from the consumers’ locations, such as their homes or offices
SMS Alerts
Customers receive an SMS to download the report through email or web portal
Polyclinic Chambers
Polyclinic chambers hosting doctors providing out-patient consultation
Customer Centric Approach
Polyclinic Chambers
Online Bookings
More convenience through online test bookings, consultations and digital test results
Suraksha Diagnostic Limited| Investor Presentation
Online Bookings
Customers can book appointments and access test reports online
17
Positioned To Leverage IT Infrastructure
LIMS integration
Our Laboratory Information Management System (LIMS) streamlines sample processing and report delivery. It ensures accuracy through barcoded labels and bi-directional analyser integration
RIS and PACS workflow
The Radiology Information System (RIS) and PACS streamline imaging workflows. They integrate with registration and dispatch systems for smooth operations
Advanced imaging tools
PACS includes DICOM viewers with MIP, MPR, and 3D tools. These support high-quality image analysis across modalities and locations
ERP-enabled operations
Our ERP system handles billing, inventory, procurement, and equipment use. It drives efficiency across all diagnostic centers
Error reduction and turnaround time
Automation reduces errors and improves turnaround tracking. It ensures reliable and consistent service across the network
Solution Provider
Suraksha’s Integrated System for Diagnostics
Suraksha Diagnostic Limited| Investor Presentation
18
Key Differentiating Factors
Polyclinic
Diversified in terms of revenue from services
4%
Revenue
49%
47%
132
Chambers1
1,000+
Doctors1
Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers
Pathology
Radiology
OPDConsultation
Revenue contribution from Pathology, Radiology and OPD Consultation (% of Q1 FY26 revenue)
Note: 1) as of 30 June 2025
Suraksha Diagnostic Limited| Investor Presentation
19
Experienced Board Of Directors
Dr. Somnath Chatterjee Chairman & Joint Managing Director
▪ Associated with Suraksha since
incorporation; 32+ years of experience in medical and diagnostics business
▪ Holds bachelor’s degree in medicine and surgery from University of Calcutta and is registered with West Bengal Medical Council
Ritu Mittal Joint Managing Director & Chief Executive Officer
▪ Associated with Suraksha since
incorporation; 28+ years of experience in the medical and diagnostics business ▪ Cleared the examination for a bachelor’s
degree in commerce from the University of Calcutta
Mr. Satish Kumar Verma Non-Executive, Non-Independent Director
▪ 40+ years of experience in management ▪ Holds a bachelor’s degree in mechanical
engineering and post-graduate diploma in engineering from Punjab University
Mr. Pradip Kumar Dutta Independent Director
Mr. Siddhartha Roy Independent Director
▪ Several years of work experience. Currently, an advisor to board at Simyog Technology
▪ 39+ years of experience ▪ Holds bachelor’s degree in law from
▪ Holds B.Tech degree in electronics &
electrical communication engineering from IIT, Kharagpur; a MS degree and doctorate in philosophy from the University of Maryland
Suraksha Diagnostic Limited| Investor Presentation
Calcutta University, and also a member of the Institute of Company Secretaries of India
Mr. Dharam Chand Dharewa Independent Director
▪ 30+ years of experience ▪ Holds bachelor’s degree in commerce from G.D. Binani Mahavidyalaya, and is practicing chartered accountant since 1987
Ms. Ishani Ray Independent Director
▪ 27+ years of experience in finance ▪ Holds bachelor’s degree and master’s
degree in commerce from the University of Calcutta; she is an associate of the Institute of Chartered Accountants of India
20
Dynamic And Diverse Management Team To Deliver Next Phase Of Growth
Ravindra K S Group Chief Financial Officer
Mamta Jain Company Secretary & Compliance Officer
Niren Kaul Chief Sales Officer
▪ Professional with over 20 years of extensive experience in the finance sector including the role of Group CFO at Medica Hospitals Group, Group Finance Controller at Narayana Hrudayalaya Limited and Group Manager- Finance at Aditya Birla Nuvo Limited
▪ He has a Bachelor’s in Commerce from Kuvempu
University and is a member of the Institute of Chartered Accountants of India
▪ 9+ years of experience including with VISA International
Limited and Dollar Industries Limited
▪ Holds a bachelor’s degree in commerce from University of Calcutta, associate member of ICSI, member of the ICWAI and diploma in business administration from Symbiosis Centre for Distance Learning
▪ 22+ years of experience, including with Bharti Hexacom
Limited and Bharti Infratel Limited
▪ Holds a bachelor’s degree in electrical engineering from
Pandit Ravishankar Shukla University, Raipur and master’s degree in business administration from University of Pune
Balgopal Jhunjhunwala Regional Business Head
Sangeeta Chakraborty General Manager, Operations
▪ 15+ years of experience
▪ 26+ years of experience
▪ Holds a bachelor’s degree in commerce from University of
Calcutta
▪ She holds a Bachelor's degree in Arts from the University of Calcutta. She previously worked in the healthcare industry, managing inventory operations and contributing to process efficiency and supply chain coordination
Suraksha Diagnostic Limited| Investor Presentation
21
Strategy And Outlook
Leveraging Strengths To Drive Competitive Advantage
Largest diagnostic chain with a dominant position in Eastern India; well-positioned to benefit from the high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North-Eastern India
Technologically advanced clinical infrastructure and trained personnel ensuring high quality and reliable diagnostic services
Track record of profitability and consistent financial performance
Integrated diagnostics provider with one-stop solution offering pathology & radiology testing, and medical consultation services
High brand recall and commitment to superior quality, driving high individual consumer business share and customer retention
Management team with robust industry experience
Suraksha Diagnostic Limited| Investor Presentation
23
Strategic Levers To Drive Future Growth
Expand footprint in Eastern and North-Eastern India through organic as well as inorganic route
Strengthen B2B and institutional partnerships to access new customer segments
Build on brand equity and service quality to drive customer retention and deliver growth
Enhance one-stop diagnostic model by augmenting medical consultation services’ share
Invest in technology to enhance diagnostic accuracy, lower turnaround time and elevate customer experience
Leverage experienced leadership for strategic decision-making and operational efficiency
Suraksha Diagnostic Limited| Investor Presentation
24
Targeting Organic And Inorganic Opportunities In Core And Adjacent Markets
Consolidate leading position in the core geography
Expand in adjacent geographies of Eastern and North-Eastern India
Supplement organic growth with selective acquisitions
Open additional diagnostic centres and increase franchisee partnerships with local entrepreneurs
Enhance the laboratory capacity and test menu by adding latest technologies
Increase home collection services
Identify key locations in Eastern and North-Eastern India
Replicate the (a) ‘hub and spoke’ model to unlock economies of scale (b) polyclinic model to drive higher number of patient footfalls
Build spoke centers around the existing hub centers in Bihar, Guwahati and Meghalaya
Selective acquisitions of and/or strategic partnerships with local diagnostic centres across Eastern and North-Eastern India
Factors while evaluating acquisition targets • Brand recognition • Customer base • Technical capability and resources
Set up more hub centres to form new clusters, and spoke centres in existing clusters
Wider geographic reach will expand the customer base as well as improve the profitability by allowing to better leverage the infrastructure
Leverage technology to elevate customer experience
Increase share of medical consultation services at diagnostic centres
Engage in Business-to-business (“B2B”) and corporate partnerships
Create a convenient one-stop solution through integration of digital technology, artificial intelligence and machine learning
Increase the touch points and engagement with customers through digital and technological initiatives
Set up more polyclinics in the existing diagnostic centres, and increase the number and specialties of doctors associated
Enhance revenue from the B2B segment to further diversify revenue mix and increase customer base & brand penetration
Achieve higher footfalls, tests per patient, and average revenue per patient
Actively seek institutional customers through referrals or internal lead-generation
Suraksha Diagnostic Limited| Investor Presentation
25
Industry Overview
Industry: Poised For High Growth; Shifting Towards Organized Market
Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28
Organized players gaining market share from standalone labs at a steady rate
CAGR 10-12%
1,275-1,375
860-870
FY24E
FY28P
Indian Diagnostic Industry (INR bn)
Pathology
56%
Radiology
44%
36-40%
13- 17%
45-49%
FY201
20- 24%
36-40%
35-39%
FY24E1
Diagnostic chains
Hospital Based
Standalone
Estimated break-up of the Indian diagnostics industry
Radiology expected to grow at a relatively faster pace
CAGR 9-11%
700-755
480-490
FY24E
FY28P
CAGR 11-13%
570-620
375-385
FY24E
FY28P
Radiology Market (INR bn)
Segment wise break-up of diagnostics market (FY24E)
Pathology Market (INR bn)
Source: CRISIL Report Note: 1) For FY20 & FY24E, Multiregional Chains account for 35-40% & 34-38% respectively of the overall Diagnostic Chains; For FY20 & FY24E, Regional Chains account for 60-65% & 62-66% respectively of the overall Diagnostic Chains
Suraksha Diagnostic Limited| Investor Presentation
27
Eastern India - An “Underserved” Market With Premium Pricing
Disparity in access to accredited testing services in Eastern(1) India relative to population needs
Region has the lowest number of NABH accredited hospitals
East India(1) market also offers premium pricing for diagnostic tests
2.50
430
1.62
1.60
Average: 1.61
187
227
0.96
North
South
West
East¹
North
South
West
70-80
55-65
80-90
80-90
North
South
West
East & North East1
Average: 179
50
East & North East
1
# NABL labs per mn population (Feb 2024)
# Region wise NABH accredited hospitals
Region-wise average diagnostic test expenditure(2) (INR)
East India(1) has the highest share of population, yet the lowest share of Indian diagnostics market
East India(1) diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28
West Bengal diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28
INR (Bn)
CAGR 10.5-12.5%
260-280
INR (Bn)
CAGR 10.5-12.5%
170-180
% share of population in East India, FY24E(1)
% share of East India(1) diagnostics market, FY24E
FY24E
FY28P
Source: CRISIL Report Note: 1) East including Northeast region is defined as: Bihar, Jharkhand, Odisha, West Bengal, Chhattisgarh: Sikkim, Arunachal Pradesh, Assam, Tripura, Mizoram, Nagaland, Manipur, Meghalaya; 2) For non-hospitalization
Suraksha Diagnostic Limited| Investor Presentation
61-63
FY24E
95-100
FY28P
28
Key Awards & Recognition
2017
Best quality in service delivery(1)
2019
Best customer service in healthcare(1)
2021
Business leader of the year(2)
2021
Awards & certificate of excellence(3)
2022
Outstanding diagnostic chain of eastern India(4)
2023
Certificate of excellence in exemplary trust & commitment towards diagnostic services(5)
Note: 1) Awarded by ABP News; 2) by the World Leadership Congress & Awards; 3) By Zee24 Ghanta; 4) by ABP Ananda; 5) at the Health Conclave 2023 organized by Zee24 Ghanta
Suraksha Diagnostic Limited| Investor Presentation
29
Company :
Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Email: investors@surakshanet.com
investors@surakshanet.com
Investor Relations Advisors :
MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services
Mr. Ashish Tendulkar ashish.tendulkar@in.mpms.mufg.com
Ms. Pooja Swami pooja.swami@in.mpms.mufg.com
Meeting Request
Link
Link Link
THANK YOU
Meeting Request
Link
Link